CXCR6 as a novel therapeutic target in allergic asthma
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2025.116005 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Nanting Zou und 11 weiteren Autor:innen. Beteiligte Einrichtung: First Clinical Medical College, School of Chinese Materia Medica and School of BasicMedical Sciences,Yunnan University of Chinese Medicine, Kunming 6…. Hauptthemen laut MEDLINE: Asthma, Receptors, CXCR6. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Kunming Institute of Zoology, Chinese Academy of Sciences, National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: C-X-C motif chemokine receptor 6 (CXCR6) has emerged as a key marker selectively expressed on pathogenic CD4+ T cells involved in various inflammatory and immune-mediated disorders. However, its expression and functional significance in CD4+ T lymphocytes-known to play a pivotal role in the pathogenesis of allergic asthma-remain poorly understood. To address this gap, we investigated the potential role of CXCR6 as a novel therapeutic target in allergic asthma. METHODS: An ovalbumin (OVA)-induced allergic asthma mouse model was established, along with in vitro differentiation of T-helper cell subsets. Multiparametric flow cytometry, RT-qPCR, and Western blotting were employed to characterize CXCR6 expression across specific cell types and tissues. CXCR6+CD4+ and CXCR6-CD4+ T cells infiltrating the lung were isolated and subjected to RNA sequencing for differential gene expression analysis. Additionally, an anti-CXCR6 monoclonal antibody was administered to selectively deplete CXCR6+ cells and assess the functional consequences of CXCR6 inhibition in allergic asthma. Key differentially expressed genes (DEGs) were further validated by RT-qPCR in lung tissue. RESULTS: CXCR6+CD4+ T cells were significantly enriched in the lungs of OVA-induced asthmatic mice and exhibited heightened secretion of intracellular cytokines IL-17 and IFN-γ, alongside increased CXCR6 and CXCL16 protein expression. In vitro polarization studies demonstrated that CXCR6 expression was selectively elevated in Th1 and Th17 cells, but not in Th2 or regulatory T (Treg) cells. RNA sequencing identified 1574 DEGs between CXCR6+ and CXCR6- CD4+ T cells, with enrichment in pathways related to chemokine signaling, Th17 cell differentiation, Th1/Th2 polarization, and asthma pathogenesis. Treatment with the anti-CXCR6 antibody effectively depleted CXCR6+CD4+ T cells and significantly downregulated CXCR6 and CXCL16 protein levels in the lungs of asthmatic mice. Notably, this intervention markedly attenuated airway inflammation, mucus hypersecretion, serum anti-OVA IgE levels, and concentrations of IL-17 A, IFN-γ, and inflammatory infiltrates in lung tissue. Furthermore, key signature genes associated with pathogenic Th17 (Il17a, Il17f, Il22, Il23), Th1 (Il1b), and Th2 (Il4, Il13) responses were substantially reduced following CXCR6 antibody treatment. CONCLUSION: Our findings demonstrate that CXCR6+CD4+ T cells are highly enriched in the lungs of OVA-induced allergic asthmatic mice and are strongly associated with pulmonary inflammation. Targeting CXCR6 represents a promising immunotherapeutic strategy for mitigating allergic asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Clinical Medical College, School of Chinese Materia Medica and School of BasicMedical Sciences,Yunnan University of Chinese Medicine, Kunming 650021, China.
- Zhenxiong County Hospital of Traditional Medicine, Zhaotong 657000, China.
- First Clinical Medical College, School of Chinese Materia Medica and School of BasicMedical Sciences,Yunnan University of Chinese Medicine, Kunming 650021, China. Electronic address: fenghuang_ynutcm@163.com.
- First Clinical Medical College, School of Chinese Materia Medica and School of BasicMedical Sciences,Yunnan University of Chinese Medicine, Kunming 650021, China. Electronic address: wanchunping1012@163.com.
Förderung
- Kunming Institute of Zoology, Chinese Academy of Sciences
- National Natural Science Foundation of China
Zitieren
APA
Zou, N., Yan, X., Wu, Z., Mo, Q., Zhang, C., Ju, M., Zhang, H., Liu, S., Huang, M., Li, X., Huang, F., & Wan, C. (2026). CXCR6 as a novel therapeutic target in allergic asthma. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.116005
Vancouver
Zou N, Yan X, Wu Z, Mo Q, Zhang C, Ju M, et al. CXCR6 as a novel therapeutic target in allergic asthma. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2025.116005
BibTeX
@article{Zou2026,
author = {Zou, Nanting and Yan, Xiaodong and Wu, Zhao and Mo, Qingyan and Zhang, Chunfei and Ju, Mingqian and Zhang, Haohong and Liu, Shuai and Huang, Maokui and Li, Xiaohong and Huang, Feng and Wan, Chunping},
title = {CXCR6 as a novel therapeutic target in allergic asthma},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2025.116005}
}
EUVIMED